Thromboembolic complications of hormonal therapy in women. Position of cardiologist
https://doi.org/10.18705/2311-4495-2020-7-4-6-11
Abstract
Thromboembolic complications is a frequent cause of acute cardiovascular events, disability and mortality. Among the factors that increase their risk in the female population using of medications, containing sex hormones is of high significance. In oral contraceptives the main — contraceptive activity belongs to gestagen, while estrogen performs an auxiliary function of menstrual cycle control. In medications used for therapy during menopause the main active substance is estrogen. Progestin provides prevention of endometrial hyperplasia. Despite the intensive search for optimal effective and safe schemes of combined hormonal drugs, the risk of thrombotic complications in patients using them both for therapeutic purposes and as contraception remains high. The article provides clinical observations illustrating the administration of hormonal therapy to women is reasonable to be discussed and agreed with cardiologists and/or general practitioners, and the patients would be informed about possible cardiovascular complications of such therapy for an adequate selfcontrol.
About the Authors
I. A. Gorlova
Federal State Budgetary Institution Almazov National Medical Research Center of the Russian Ministry of Health
Russian Federation
Competing Interests: not
Russian Federation
Gorlova Irina Aleksandrovna - PhD, Research Associate, Department of Preventive Cardiology.
Akkuratova str. 2, Saint Petersburg, 197341
Competing Interests: not
M. Y. Omelchenko
Federal State Budgetary Institution Almazov National Medical Research Center of the Russian Ministry of Health
Russian Federation
Competing Interests: not
Russian Federation
Omelchenko Marina Yurievna - PhD, Research Associate, Department of Preventive Cardiology.
Saint Petersburg
Competing Interests: not
L. A. Sokolova
Federal State Budgetary Institution Almazov National Medical Research Center of the Russian Ministry of Health
Russian Federation
Competing Interests: not
Russian Federation
Sokolova Lyudmila Andreevna - Dr. Sci., Professor, Leading Research Associate, Department of Preventive Cardiology.
Saint Petersburg
Competing Interests: not
B. B. Bondarenko
Federal State Budgetary Institution Almazov National Medical Research Center of the Russian Ministry of Health
Russian Federation
Competing Interests: not
Russian Federation
Bondarenko Boris Borisovich - Dr. Sci., Professor, Chief Research Associate, Department of Preventive Cardiology.
Saint Petersburg
Competing Interests: not
References
1. Shishkova VN. Modern oral contraception and risk of thrombosis. Zhurnal mezhdunarodnoj mediciny=Joumal of the international medicine. 2013;1(2):56-61. In Russian
2. Cagnacci A. Hormonal contraception: venous and arterial disease. Eur. J. Contracept. Reprod. Health Care. 2017;22(3): 191-199.
3. Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular triats, and all-cause mortality: a systematic review and meta-analisis. JAMA Cardiol. 2016;1(7):767-776.
4. Kuznetsova IV, Sukhanova GA. Contraception and risk of arterial thrombosis. RMZh. Mother and child. 2013;23(21):1128-1133. In Russian
5. van Hylckama Vlieg A, Middeldorp S. Hormone therapies and venous thromboembolism: where are we now? J. Thromb. Haemost. 2011;9(2):257-266.
6. Barsoum MK, Heit JA, Ashrani AA, et al. Is progestin an independent risk factor for incident venous thromboembolism? A population-based case-control study. Thromb. Res. 2010;126(5):373-378.
7. Stocco B, Fumagalli HF, Franceschini SA, et al. Comparative study of the effects of combined oral contraceptives in hemostatic variables: an observational preliminary study. Medicine. 2015; 94(4): e385.
8. Scarabin P-Y. Hormone therapy and venous thromboembolism among postmenopausal women. Front. Horm. Res. 2014; 43: 21-32.
9. Siegerink B, Maino A, Algra A, et al. Hypercoagulability and the risk of myocardial infarction and ischemic stroke in young women. J. Thromb. Haemost. 2015; 13(9): 1568-1575.
10. Anderson Jr FA, Spenser FA. Risk factors for venous thromboembolism. Circulation. 2003;107 (23 Suppl 1): I9-16.
11. Farris M, Bastianelli C, Rosato E, et al. Pharmacodynamics of combined estrogen-progestin oral contraceptives: 2. Effects on hemostasis. Expert. Rev. Clin. Pharmacol. 2017; 10(10): 1129-1144.
12. Canonico M. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Maturitas. 2015; 82(3): 304-307.
13. Africander D, Verhoog N, Hapgood JP. Molecular mechanisms of steroid receptor-mediated actions by synthetic progestins used in HRT and contraception. Steroids. 2011; 76(7): 636-652.
14. Atsma F, Bartelink M-LEL, Grobbee DE, et al. Postmenopausal status and early menopause as independent risk factors for cardiovascular disease: a meta-analysis. Menopause. 2006; 13(2): 265-279.
15. Kuznetsov MR, Papysheva OV. Menopausal hormone therapy and venous thromboembolic complications: what is the relationship? Doctor. Py. 2019;11(166):68-73.
16. Palacios S, Mejia A. Progestogen safety and tolerance in hormonal replacement therapy. Expert. Opin. Drug Saf. 2016;15(11):1515-1525.
17. Lidegaard 0. Severely biased review of studies assessing the risk of venous thrombosis in users of drospirenone-containing oral contraceptives. BJOG. 2018; 125(8): 929-931.
18. Salobir BG, Keber I, Vrabic L. A randomized, placebo-controlled trial of the effects of continuous combined hormone replacement therapy on coagulation and fibrinolytic systems in healthy postmenopausal women. Fertil. Steril. 2002; 78(6): 1178-1183.
19. Ceballos C, Ribes C, Amado JA, et al. Venous endothelial function in postmenopausal women who are receiving long-term estrogen and progestagen therapy. Fertil. Steril. 2000;74(2):268-273.
20. Regidor PA, Colli E, Schindler AE. Drospirenone as estrogen-free pill and hemostasis: coagulatory study results comparing a novel 4 mg formulation in a 24 + 4 cycle with desogestrel 75 pg per day. Gynecol. Endocrinol. 2016;32(9):749-751.
Review
For citations:
Gorlova I.A., Omelchenko M.Y., Sokolova L.A., Bondarenko B.B. Thromboembolic complications of hormonal therapy in women. Position of cardiologist. Translational Medicine. 2020;7(4):6-11. (In Russ.) https://doi.org/10.18705/2311-4495-2020-7-4-6-11
Views:
636
Email this article 